R3 Stem Cell launches MUSE therapy in South Africa

R3 Stem Cell has launched MUSE stem cell therapy in South Africa, opening access to the regenerative treatment through local physicians and new dosing tiers. The expansion brings a therapy platform that the company says has shown promise in published research for neurological conditions to patients who previously often had to travel abroad for advanced cell care.

Why it matters: - South African patients now have local access to MUSE stem cell therapy, reducing the need to travel internationally for advanced regenerative care. - The launch expands R3 Stem Cell’s footprint in Africa and adds South Africa to its global network of Centers of Excellence. - The program also extends the company’s R3 CARES autism registry initiative into South Africa.

What happened: - R3 Stem Cell announced the official launch of MUSE stem cell therapy in South Africa on September 23, 2026. - The launch is based in Johannesburg, Gauteng, South Africa. - The company describes itself as the world’s largest provider of regenerative medicine therapies, with more than 80 Centers of Excellence across eight countries. - R3 Stem Cell said the South Africa program starts immediately and will be delivered under its clinical framework with local physician partners.

The details: - MUSE stands for Multilineage-differentiating Stress Enduring. - MUSE cells are a naturally occurring, non-genetically modified stem cell population first identified in connective tissue and bone marrow. - Published research to date has shown an acceptable safety profile and positive effects for neurological conditions including ALS, MS, stroke, autism, brain injury and spinal cord injury. - A compilation of peer-reviewed research is available here. - R3 Stem Cell will offer three dosing tiers in South Africa: 20 million cells for $7,495, 50 million cells for $12,950 and 100 million cells for $18,950. - The company lists the 20 million-cell dose as an entry-level protocol for single-region focus, the 50 million-cell dose as a standard protocol for moderate-complexity cases and the 100 million-cell dose as an advanced protocol for multi-region or higher-complexity cases. - Final dosing recommendations are made case by case after consultation with an R3 Stem Cell-affiliated physician. - R3 Stem Cell said South Africa was chosen because of its medical infrastructure, rising demand for regenerative treatment and physician readiness.

Between the lines: - The launch gives R3 Stem Cell a local route into a market where access to advanced cell therapy has been limited. - The company is positioning MUSE as a differentiated platform because of its multilineage potential, stress tolerance, tissue-homing behavior and published safety profile. - The move also signals a broader push to scale regenerative medicine offerings across Africa, with South Africa serving as the initial regional anchor.

What's next: - R3 Stem Cell said it will continue working with local physician partners to maintain the same clinical standards used across its other Centers of Excellence. - The company expects South Africa to serve as the starting point for broader expansion across Africa. - Patients interested in a consultation can contact R3 Stem Cell at +27311001808 or info@r3stemcell.com.

The bottom line: - R3 Stem Cell is bringing a new regenerative treatment option to South Africa, pairing local access with a tiered pricing model and a broader African expansion strategy.